Tobramycin Injection
NDC Package 36000-244-05
Package Information
Tobramycin injection is a medication used to treat eye infections. This formulation utilizes a injection delivery system. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 36000-244 and is authorized under FDA application ANDA206965.
Identification & Billing
- RxCUI: 597823 - tobramycin 40 MG/ML Injectable Solution
- RxCUI: 597823 - tobramycin (as tobramycin sulfate) 40 MG/ML Injectable Solution
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 36000 - Baxter Healthcare Corporation
- 36000-244 - Tobramycin
- 36000-244-05 - 5 VIAL in 1 BLISTER PACK / 2 mL in 1 VIAL
- 36000-244 - Tobramycin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (36000-244). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 36000-244-05 identifies a specific commercial package of 5 vial in 1 blister pack / 2 ml in 1 vial of Tobramycin, a human prescription drug labeled by Baxter Healthcare Corporation. This injection is formulated for intramuscular; intravenous use and contains tobramycin sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Corporation on July 15, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat eye infections. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.
How is this Baxter Healthcare Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 36000024405. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.